ADAKVEO 판매 예측 및 시장 규모 분석(2034년)

Key Factors Driving ADAKVEO Growth

1. First-in-class mechanism targeting P-selectin

• ADAKVEO is a humanized monoclonal antibody targeting P-selectin, reducing adhesion of sickled cells and preventing vaso-occlusion.
• It was the first FDA-approved therapy with this mechanism (2019) for reducing vaso-occlusive crises (VOCs).
• This differentiation supports adoption, especially in patients inadequately controlled on hydroxyurea.

Impact: Strong clinical differentiation positioned ADAKVEO as an innovative biologic in SCD, supporting early uptake.

2. Demonstrated reduction in vaso-occlusive crises (key clinical driver)

• VOCs are the primary cause of hospitalization in SCD, with ~200,000 ER visits annually in the U.S.
• Clinical trials (e.g., SUSTAIN) showed clinically meaningful reduction in VOC frequency, a major unmet need.

Impact: Clear efficacy on a clinically meaningful endpoint drives physician adoption and payer justification.

3. Strong early commercial uptake with rapid growth trajectory

• ADAKVEO generated ~USD 34 million sales early in launch phase (2020 period).
• Sales reached ~USD 186 million in 2022, reflecting significant uptake post-launch.
• Growth from 2020 to 2022 was ~77%, indicating rapid expansion.

4. Blockbuster potential supported by company projections

• Novartis projected ADAKVEO could achieve >USD 1 billion annual sales (blockbuster status).

Forecast Insight:

• While actual uptake has been slower than blockbuster expectations, long-term growth potential remains tied to:
• Expanded geographic access
• Combination therapy use
• Broader SCD diagnosis and treatment rates

5. Large and growing Sickle Cell Disease (SCD) patient population

• ~100,000 patients in the US alone; millions globally.
• Global SCD burden is rising, with ~7.74 million patients in 2021, and increasing incidence projected.

ADAKVEO Recent Developments

• The European Medicines Agency (EMA) revoked the marketing authorization for ADAKVEO in August 2023 following the STAND trial, which failed to demonstrate a significant reduction in vaso-occlusive crises compared to a placebo, contradicting earlier Phase II results.

"ADAKVEO Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of ADAKVEO for approved indication like Vaso-occlusive crisis; as well as potential indication like riapism, Vascular disorders, and Myelofibrosis in the 7MM. A detailed picture of ADAKVEO's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the ADAKVEO for approved and potential indications. The ADAKVEO market report provides insights about ADAKVEO's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ADAKVEO performance, future market assessments inclusive of the ADAKVEO market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ADAKVEO sales forecasts, along with factors driving its market.

ADAKVEO Drug Summary

ADAKVEO (Crizanlizumab) is a prescription medication developed by Novartis, approved by the FDA in 2019, and indicated to reduce the frequency of vaso-occlusive crises (VOCs), also known as pain crises, in adults and pediatric patients aged 16 years and older with sickle cell disease. As a targeted biologic and humanized IgG2 monoclonal antibody, it functions as a selectin inhibitor by binding to P-selectin on the surface of activated endothelial cells and platelets, thereby preventing sickle-shaped red blood cells from adhering to vessel walls and blocking interactions with leukocytes and platelets that lead to vaso-occlusion. Administered intravenously over 30 minutes at a dose of 5 mg/kg-initially at Week 0, Week 2, and every 4 weeks thereafter-it can be used as monotherapy or as an add-on to hydroxyurea (HU/HC) in patients for whom HU/HC is inappropriate or inadequate, and it is supplied as a 10 mg/mL preservative-free solution in single-dose 10 mL vials. The report provides ADAKVEO's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ADAKVEO Market Report

The report provides insights into:

• A comprehensive product overview including the ADAKVEO MoA, description, dosage and administration, research and development activities in approved indications like Vaso-occlusive crisis; as well as potential indication like riapism, Vascular disorders, and Myelofibrosis.
• Elaborated details on ADAKVEO regulatory milestones and other development activities have been provided in ADAKVEO market report.
• The report also highlights ADAKVEO's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ADAKVEO market report also covers the patents information, generic entry and impact on cost cut.
• The ADAKVEO market report contains current and forecasted ADAKVEO sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ADAKVEO market report also features the SWOT analysis with analyst views for ADAKVEO in approved and potential indications.

Methodology:

The ADAKVEO market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ADAKVEO Analytical Perspective by DelveInsight

• In-depth ADAKVEO Market Assessment

This ADAKVEO sales market forecast report provides a detailed market assessment of ADAKVEO for approved indication like Vaso-occlusive crisis; as well as potential indication like riapism, Vascular disorders, and Myelofibrosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ADAKVEO sales data uptil 2034.

• ADAKVEO Clinical Assessment

The ADAKVEO market report provides the clinical trials information of ADAKVEO for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ADAKVEO Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ADAKVEO Market Potential & Revenue Forecast

• Projected market size for the ADAKVEO and its key indications
• Estimated ADAKVEO sales potential (ADAKVEO peak sales forecasts)
• ADAKVEO Pricing strategies and reimbursement landscape

ADAKVEO Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ADAKVEO Market positioning compared to existing treatments
• ADAKVEO Strengths & weaknesses relative to competitors

ADAKVEO Regulatory & Commercial Milestones

• ADAKVEO Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ADAKVEO Clinical Differentiation

• ADAKVEO Efficacy & safety advantages over existing drugs
• ADAKVEO Unique selling points

ADAKVEO Market Report Highlights

• In the coming years, the ADAKVEO market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ADAKVEO companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ADAKVEO's dominance.
• Other emerging products for Vaso-occlusive crisis; as well as potential indication like riapism, Vascular disorders, and Myelofibrosis are expected to give tough market competition to ADAKVEO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ADAKVEO in approved and potential indications.
• Analyse ADAKVEO cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ADAKVEO sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ADAKVEO in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of ADAKVEO? How strong is ADAKVEO's clinical and commercial performance?
• What is ADAKVEO's clinical trial status in each individual indications such as Vaso-occlusive crisis; as well as potential indication like riapism, Vascular disorders, and Myelofibrosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ADAKVEO Manufacturers?
• What are the key designations that have been granted to ADAKVEO for approved and potential indications? How are they going to impact ADAKVEO's penetration in various geographies?
• What is the current and forecasted ADAKVEO market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ADAKVEO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ADAKVEO for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ADAKVEO? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. ADAKVEO Overview in approved indications like Vaso-occlusive crisis; as well as potential indication like riapism, Vascular disorders, and Myelofibrosis

• 2.1. Product Detail
• 2.2. ADAKVEO Clinical Development
  • 2.2.1. ADAKVEO Clinical studies
  • 2.2.2. ADAKVEO Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. ADAKVEO Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging ADAKVEO Therapies)

5. ADAKVEO Market Assessment

• 5.1. ADAKVEO Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. ADAKVEO Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. ADAKVEO Market Size in the United States for approved and potential indications
  • 5.3.2. ADAKVEO Market Size in Germany for approved and potential indications
  • 5.3.3. ADAKVEO Market Size in France for approved and potential indications
  • 5.3.4. ADAKVEO Market Size in Italy for approved and potential indications
  • 5.3.5. ADAKVEO Market Size in Spain for approved and potential indications
  • 5.3.6. ADAKVEO Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. ADAKVEO Market Size in Japan for approved and potential indications

6. ADAKVEO SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options